Plasmid DNA has long been the workhorse of cell and gene therapy — supporting countless clinical programs and enabling many of the field’s most important breakthroughs. At the same time,…
In gene therapy manufacturing, viral vectors have long been the primary method for gene modification. However, recent innovations, combined with the evolving demands of the genetic medicines market, are driving…
This white paper explores how Touchlight is redefining DNA payload design for next-generation gene editing and non-viral gene therapy. It introduces innovative circular DNA architectures such as mbDNA, sscDNA, hsscDNA,…
As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA…
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP…
In this session, Elena Stoyanova, PhD (Touchlight) introduces mbDNA™ (Megabulb DNA), a novel single-stranded circular DNA template featuring a customizable stem region and fully user-defined sequence. Chesney Michels, PhD (ElevateBio)…
Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Touchlight, a pioneering leader in DNA manufacturing technologies, has been named the 2025 FOYA Category Winner for Innovation in the International Society for Pharmaceutical Engineering (ISPE) Facility of the Year…